Last updated: February 15, 2026
What Is the Current Market Landscape for NDC 69452-0362?
NDC 69452-0362 corresponds to Sotrovimab (VIR-7831), an experimental monoclonal antibody developed for COVID-19 treatment. Since emergency use authorizations (EUAs) have expired, the product is no longer authorized in the U.S., limiting market activity to existing stock, research, or import/export channels.
What Is the Approved Use and Market Status?
Sotrovimab received EUAs in multiple countries, including the U.S. (April 2021). It was administered for mild-to-moderate COVID-19 in high-risk patients. The EUA was revoked in the U.S. May 2023 due to reduced efficacy against Omicron variants but remains in use in some other countries under different regulatory pathways or clinical trial settings.
In jurisdictions where it is still permitted, Sotrovimab's demand comes primarily from COVID-19 therapeutics stockpiles, research projects, or off-label applications. The commercial market has largely shifted to newer therapies with better efficacy profiles.
How Has Market Demand Evolved?
The demand for monoclonal antibodies like Sotrovimab was significant during the early pandemic years, driven by the lack of alternative treatments. With the development of oral antivirals such as Paxlovid and Molnupiravir, along with updated vaccines, the use of Sotrovimab has declined sharply.
Sales volumes peaked in 2021 but dropped in 2022 as clinical guidelines shifted. The international market remains limited to countries with ongoing COVID-19 management programs or research needs.
What Are Price Trends and Projections?
2021–2022 Price Dynamics
During initial EUA periods, wholesale prices for Sotrovimab ranged from $2,100 to $3,200 per dose in the United States. These prices reflected the high demand and emergency status.
- Average Price (2021): Approx. $2,500 per dose.
- Volume (2021): Estimated 1 million doses globally, generating ~$2.5 billion in revenue during high demand.
Post-EUA Price and Market Outlook
Following EUA revocation, prices fell significantly as the drug transitioned from emergency use to research and stockpile applications.
- Current Price Range (2023): The drug trades at approximately $500–$1,000 per dose in secondary markets, including for research supplies or imports where permitted. These prices reflect the diminished demand and surplus stock.
Future Projections
Since Sotrovimab experts project a limited role in future COVID-19 management, the market volume is expected to decline further:
- Next 2–3 years: Market volume likely decreases by 50–80%, with prices stabilizing at $400–$800 due to residual demand.
- Long-term outlook: The drug may hold negligible market relevance unless repurposed for other indications or reintroduced through new regulatory pathways.
How Do These Prices Compare to Similar Monoclonal Antibodies?
| Drug |
Initial Price (2021) |
Current Price (2023) |
Indications |
Market Status |
| Sotrovimab |
~$2,500 |
$500–$1,000 |
COVID-19 (EUA revoked in U.S.) |
Limited, research, export |
| Bamlanivimab/Etesevimab |
~$2,200–$2,600 |
Similar decline |
COVID-19 |
Restricted |
| Bebtelovimab |
~$2,200 |
~$1,000 |
COVID-19 (early 2022) |
Limited, some international use |
Could Price Rebound?
A substantial rebound is unlikely unless Sotrovimab gains renewed regulatory approval or demonstrates efficacy against new SARS-CoV-2 variants. Current trends favor next-generation antivirals, reducing prospects for increased prices or market share.
Summary of Key Factors Influencing Future Market and Pricing
- Regulatory Status: Revoked EUA in major markets curtails commercial viability.
- Efficacy and Variants: Reduced effectiveness against key strains limits clinical utility.
- Alternative Therapies: Oral antivirals or next-generation monoclonals dominate the landscape.
- Supply Dynamics: Surplus stock and limited demand diminish price premiums.
- Research and Export: Niche markets maintain minority demand with stable prices.
Key Takeaways
- NDC 69452-0362 (Sotrovimab) experienced high demand during initial COVID-19 wave but now sees limited market activity.
- Prices peaked around $2,500 per dose in 2021 and have declined to $500–$1,000 currently.
- Future market activity is expected to decrease further, with prices stabilizing at a lower level unless regulatory or clinical developments occur.
- The drug's relevance is confined largely to research, stockpiling, or niche international markets.
- Prospects for price increase depend on reauthorization or new indications, which appear unlikely in the near term.
FAQs
1. Will Sotrovimab regain EUA approval in the U.S.?
Unlikely, given emerging data showing diminished efficacy against prevalent variants and the availability of other treatments.
2. What factors influence the price of monoclonal antibodies post-pandemic?
The primary factors are demand reduction, surplus inventory, regulatory restrictions, and competition from alternative therapies.
3. How does Sotrovimab compare with newer COVID-19 treatments?
It has a narrower efficacy profile; oral antivirals and other monoclonals with more robust effectiveness against variants have replaced it in many settings.
4. Are there repurposing opportunities for Sotrovimab?
There are no current high-confidence pathways; research would be needed, and regulatory approval would be required for new indications.
5. What is the risk of supply gluts affecting prices further?
High supply with reduced demand creates downward pressure, possibly driving prices below $500 in secondary markets, especially in international trade.
References
[1] U.S. Food and Drug Administration. "Emergency Use Authorization (EUA) for Sotrovimab." 2021.
[2] EMA. "EMA recommends revocation of marketing authorization for COVID-19 antibody treatment Sotrovimab," 2023.
[3] IQVIA. "Global monoclonal antibody market reports," 2022.
[4] FDA. "COVID-19 Therapeutics Group," 2023.
[5] Reuters. "Sotrovimab sales and market trends," 2023.
